Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.
The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.
Corcept Therapeutics (CORT) officer Joseph D. Lyon reported a proposed sale of 10,000 common shares, with an aggregate market value of $1,152,300.00, on October 1, 2026, through Stifel Nicolaus. The shares are listed as acquired from the issuer through a stock option exercise for cash. Earlier reported sales were 1,540 shares for $175,725.77 on August 3, 2026, and 10,000 shares for $1,134,423.74 on September 14, 2026.
Corcept Therapeutics Inc. Chief Business Officer Gary Charles Robb reported giving 17,100 common shares on September 24, 2026, leaving 14,056 shares held directly; that balance includes shares underlying unvested restricted stock awards. On the same date, two separate transactions of 5,000 shares each were reported as acquisitions in custodial accounts under the Uniform Transfers to Minors Act. Robb was trustee of a revocable trust holding 39,716 shares indirectly.
Corcept Therapeutics Incorporated (CORT) announced that Sean Maduck, President of its Endocrinology division, will retire effective October 1, 2026, and that Justin Gunn will succeed him and fully assume the role that day. Gunn will join the Executive Team and report to Chief Executive Officer Joseph K. Belanoff.
Maduck will provide consulting services to the CEO and executive management under an agreement effective October 1, 2026, with an initial term through September 30, 2027, unless terminated earlier. His cash fee is $57,000 per month, and his previously awarded, outstanding stock options will continue vesting on their original schedules during the consulting term. Either party may terminate with 30 days’ prior written notice. The company stated his resignation was not due to disagreement over its operations, financial statements, policies or practices.
CORCEPT THERAPEUTICS INC (CORT) reported that Roberto Wandenkolk Vieira, President, Oncology, sold 296 shares of common stock on September 16, 2026 at $100.82 per share in an open-market transaction under a Rule 10b5-1 trading plan. After the sale, he held 3,946 shares directly, including 1,347 unvested restricted stock award shares scheduled to vest in full on the one-year anniversary of each grant date subject to conditions.
Corcept Therapeutics Inc. (CORT) reports that Chief Business Officer Gary Charles Robb exercised options for 17,493 shares of common stock on September 17, 2026 at an exercise price of $8.27 per share, converting a fully exercisable option into common shares. Following this transaction, he holds 31,156 common shares directly, including 1,663 shares underlying unvested restricted stock awards that vest on the one-year anniversaries of their grant dates if conditions are met, and continues to hold 182,507 options directly that expire on February 10, 2027. He also has indirect ownership of 39,716 common shares through a revocable trust for which he is trustee, plus additional indirect holdings in custodial accounts for his children, and no Rule 10b5-1 trading plan is reported.
CORCEPT THERAPEUTICS INC (CORT) reported that its Chief Accounting & Technology Officer, Joseph Douglas Lyon, exercised stock options for a total of 10,000 shares of common stock on September 14, 2026, at exercise prices of $11.35 and $13.56 per share, and sold 10,000 shares the same day in open-market or private transactions under a Rule 10b5-1 trading plan.
The sales were executed in two tranches at weighted average prices of $113.32 and $114.12 per share, and the filing notes that Lyon also holds unvested restricted stock awards scheduled to vest one year after their respective grant dates, subject to specified service conditions.
CORCEPT THERAPEUTICS INC (CORT) director James N. Wilson reported indirect sales of a total of 10,000 shares of common stock on September 15, 2026 by the James N. Wilson and Pamela D. Wilson Trust. The shares were sold in open-market transactions under a Rule 10b5-1 trading plan adopted on March 12, 2026, at weighted average prices between $109.66 and $111.705 per share. Wilson has voting power over the trust’s shares under voting agreements and disclaims beneficial ownership except to the extent of his pecuniary interest. The filing also reports indirect holdings of 200,000 shares each in the James N. Wilson 2025 Grantor Retained Annuity Trust and the Pamela D. Wilson 2025 Grantor Retained Annuity Trust as of September 15, 2026.
Corcept Therapeutics Inc. (CORT) insider James N. Wilson filed a Rule 144 notice indicating an intention to sell up to 30,000 shares of common stock, to be sold through The Charles Schwab Corporation, with an aggregate market value of $3,344,400. The shares relate to stock option awards dated February 24, 2026. Wilson also reported prior sales of 10,000 shares for $882,986 on July 15, 2026 and 10,000 shares for $1,114,261 on August 14, 2026.
CORCEPT THERAPEUTICS INC (CORT) received a Rule 144 notice from officer Joseph Douglas Lyon regarding a planned sale of company stock. The notice reports an intended sale of 10,000 shares of common stock, to be issued through a stock option exercise for cash on September 14, 2026, with sales through broker Stifel Nicolaus on NASDAQ.
The filing also reports that over the prior three months, Joseph D. Lyon sold 1,540 shares of common stock on August 3, 2026. Rule 144 requires this disclosure of planned and recent sales by affiliates of the issuer.
CORCEPT THERAPEUTICS INC (CORT) reported that Chief Development Officer William Guyer acquired common stock on September 1, 2026 through company equity programs. He purchased 164 shares under a purchase plan established under the 2024 Incentive Award Plan at $113.38 per share, based on that day's closing price, and received an additional 164 shares as unvested restricted stock awards that will vest in full one year after grant if he remains the beneficial owner of the purchase-plan shares and meets plan requirements. Separate unvested restricted stock awards granted on December 1, 2025, March 2, 2026 and June 1, 2026 also remain outstanding and vest on their respective one-year anniversaries subject to conditions. No Rule 10b5-1 trading plan is reported.